These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 28642115)

  • 1. Anti-TNFα therapy in inflammatory lung diseases.
    Malaviya R; Laskin JD; Laskin DL
    Pharmacol Ther; 2017 Dec; 180():90-98. PubMed ID: 28642115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of TNFalpha in pulmonary pathophysiology.
    Mukhopadhyay S; Hoidal JR; Mukherjee TK
    Respir Res; 2006 Oct; 7(1):125. PubMed ID: 17034639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Tumor Necrosis Factor Alpha to Mitigate Lung Injury Induced by Mustard Vesicants and Radiation.
    Malaviya R; Laskin JD; Businaro R; Laskin DL
    Disaster Med Public Health Prep; 2023 Oct; 17():e553. PubMed ID: 37848400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of Nitrogen Mustard-Induced Pulmonary Injury and Fibrosis by Anti-Tumor Necrosis Factor-α Antibody.
    Malaviya R; Sunil VR; Venosa A; Verissimo VL; Cervelli JA; Vayas KN; Hall L; Laskin JD; Laskin DL
    Toxicol Sci; 2015 Nov; 148(1):71-88. PubMed ID: 26243812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of flavonoids extracted from licorice on lipopolysaccharide-induced acute pulmonary inflammation in mice.
    Xie YC; Dong XW; Wu XM; Yan XF; Xie QM
    Int Immunopharmacol; 2009 Feb; 9(2):194-200. PubMed ID: 19071231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the proinflammatory cytokine tumor necrosis factor-α to alleviate cardiopulmonary bypass-induced lung injury (review).
    Gao M; Xie B; Gu C; Li H; Zhang F; Yu Y
    Mol Med Rep; 2015 Apr; 11(4):2373-8. PubMed ID: 25483004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors?
    Pascher A; Klupp J
    BioDrugs; 2005; 19(4):211-31. PubMed ID: 16128605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics beyond TNF-α inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders.
    Tougaard P; Zervides KA; Skov S; Hansen AK; Pedersen AE
    Immunopharmacol Immunotoxicol; 2016; 38(1):29-38. PubMed ID: 26810853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained sensitizing effects of tumor necrosis factor alpha on sensory nerves in lung and airways.
    Lin RL; Gu Q; Khosravi M; Lee LY
    Pulm Pharmacol Ther; 2017 Dec; 47():29-37. PubMed ID: 28587842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-17A: A Potential Therapeutic Target in Chronic Lung Diseases.
    Shaikh SB; Prabhu A; Bhandary YP
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):921-928. PubMed ID: 30652654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury.
    Zhang Y; Liang D; Dong L; Ge X; Xu F; Chen W; Dai Y; Li H; Zou P; Yang S; Liang G
    Respir Res; 2015 Mar; 16(1):43. PubMed ID: 25889862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs.
    Sharma R; Kaundal RK; Sharma SS
    Pulm Pharmacol Ther; 2009 Jun; 22(3):183-9. PubMed ID: 19073273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Roles of Galectin-3 in Pulmonary Diseases.
    Jia Q; Yang Y; Yao S; Chen X; Hu Z
    Lung; 2024 Aug; 202(4):385-403. PubMed ID: 38850292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases.
    Girolomoni G; Pastore S; Albanesi C; Cavani A
    Curr Opin Investig Drugs; 2002 Nov; 3(11):1590-5. PubMed ID: 12476958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte trafficking.
    Tomankova T; Kriegova E; Liu M
    Am J Physiol Lung Cell Mol Physiol; 2015 Apr; 308(7):L603-18. PubMed ID: 25637606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrative stress in inflammatory lung diseases.
    Sugiura H; Ichinose M
    Nitric Oxide; 2011 Aug; 25(2):138-44. PubMed ID: 21440655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases].
    Régent A; Mouthon L
    Presse Med; 2009 May; 38(5):761-73. PubMed ID: 19349142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
    Baughman RP; Iannuzzi M
    BioDrugs; 2003; 17(6):425-31. PubMed ID: 14614765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of pulmonary inflammation by mesenchymal cells.
    Alkhouri H; Poppinga WJ; Tania NP; Ammit A; Schuliga M
    Pulm Pharmacol Ther; 2014 Dec; 29(2):156-65. PubMed ID: 24657485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases.
    Lee IT; Yang CM
    Biochem Pharmacol; 2012 Sep; 84(5):581-90. PubMed ID: 22587816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.